Jazz Pharmaceuticals plc (JAZZ)

Check out top investors' recommendation for JAZZ
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
193.64
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company’s products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson’s disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin’s lymphoma; Xenazine to treat movement disorders associated with Huntington’s chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Gary Nachman Susquehanna Financial Group Buy   Sep 19, '17     196.00  Sep 19, '18  N/A 
Jessica Fye JPMorgan Buy   Sep 18, '17     190.00  Sep 18, '18  N/A 
David Amsellem Piper Jaffray Buy   Sep 14, '17     177.00  Sep 14, '18  N/A 
Randall Stanicky Canaccord Genuity Buy   Sep 14, '17     210.00  Sep 14, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Aug 30, '17     190.00  Aug 30, '18  N/A 
William Tanner Lazard Capital Markets Buy   Aug 29, '17       Aug 29, '18  N/A 
Ken Cacciatore Cowen And Company Buy   Aug 21, '17     190.00  Aug 21, '18  N/A 
Randall Stanicky Canaccord Genuity Buy   Aug 07, '17     210.00  Aug 07, '18  N/A 
Gary Nachman Susquehanna Financial Group Buy   Aug 03, '17       Aug 03, '18  N/A 
Gregg Gilbert BofA Merrill Lynch Buy   Jul 17, '17     178.00  Jul 17, '18  N/A 
David Amsellem Piper Jaffray Buy   Jul 14, '17     182.00  Jul 14, '18  N/A 
Randall Stanicky Canaccord Genuity Buy   Jun 27, '17     210.00  Jun 27, '18  N/A 
William Tanner Lazard Capital Markets Buy   Jun 27, '17     197.00  Jun 27, '18  N/A 
Randall Stanicky Canaccord Genuity Buy   May 15, '17     210.00  May 15, '18  N/A 
Ken Cacciatore Cowen And Company Buy   May 10, '17     190.00  May 10, '18  N/A 
Michael Schmidt Leerink Swann Llc Buy   Apr 27, '17     179.00  Apr 27, '18  N/A 
Irina Rivkind Cantor Fitzgerald Buy   Apr 07, '17     197.00  Apr 07, '18  N/A 
Ken Cacciatore Cowen And Company Buy   Mar 20, '17     190.00  Mar 20, '18  N/A 
Michael Schmidt Leerink Swann Llc Buy   Mar 01, '17     170.00  Mar 01, '18  N/A 
Irina Rivkind Cantor Fitzgerald Buy   Mar 01, '17     187.00  Mar 01, '18  N/A 
< previous12345